Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection

International Journal for Parasitology

Volumn 40, Issue 13, 2010, Pages 1549-1561

  Takayama, Eiji ^a   Ono, Takeshi ^a   Carnero, Elena ^b   Umemoto, Saori ^a   Yamaguchi, Yoko ^a   Kanayama, Atsuhiro ^a   Oguma, Takemi ^a   Takashima, Yasuhiro ^c   Tadakuma, Takushi ^a   García Sastre, Adolfo ^b   Miyahira, Yasushi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c GIFU UNIVERSITY   (Japan)

Author keywords

CD8+ T cells; Recombinant adenovirus; Recombinant influenza virus; Recombinant vaccinia virus; Trypanosoma cruzi

Indexed keywords

ADENOVIRUS VECTOR; CD8 ANTIGEN; CD8+ T LYMPHOCYTE VACCINE; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; PARASITE ANTIGEN; UNCLASSIFIED DRUG; VACCINE; VIRUS VECTOR;

ANTIGEN; CELL ORGANELLE; DISEASE VECTOR; IMMUNIZATION; PROTOZOAN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; VACCINATION; VIRUS;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHAGAS DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; INFECTION RESISTANCE; INFLUENZA VIRUS; LYMPHOCYTE COUNT; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TRYPANOSOMA CRUZI; VACCINIA VIRUS;

ADENOVIRIDAE; ANIMALS; ANTIGENS, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; CHAGAS DISEASE; EPITOPES, T-LYMPHOCYTE; FEMALE; GENETIC VECTORS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; MICE; ORTHOMYXOVIRIDAE; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; TRYPANOSOMA CRUZI; VACCINATION; VACCINIA VIRUS; VIRUSES;

ADENOVIRIDAE; ORTHOMYXOVIRIDAE; TRYPANOSOMA CRUZI; VACCINIA VIRUS;

EID: 77957749173     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpara.2010.05.011     Document Type: Article

References (58)

1. + T cell efficacy in vaccination and disease. Nat. Med. 2008, 14:623-628.
2. Araki K., Turner A.P., Shaffer V.O., Gangappa S., Keller S.A., Bachmann M.F., Larsen C.P., Ahmed R. MTOR regulates memory CD8 T-cell differentiation. Nature 2009, 460:108-112.
3. Bejon P., Ogada E., Mwangi T., Milligan P., Lang T., Fegan G., Gilbert S.C., Peshu N., Marsh K., Hill A.V. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS ONE 2007, 2:e707.
4. + T cells reveals the existence of different memory T-cell subsets in the peripheral blood and liver. J. Virol. 2007, 81:945-953.
5. Bruna-Romero O., Gonzalez-Aseguinolaza G., Hafalla J.C., Tsuji M., Nussenzweig R.S. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Natl. Acad. Sci. USA 2001, 98:11491-11496.
6. Chagas C. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., agente etiolojico de nova entidade morbida do homem. Mem. Inst. Oswaldo Cruz 1909, 1:159-218.
7. Doherty P.C., Kelso A. Toward a broadly protective influenza vaccine. J. Clin. Invest. 2008, 118:3273-3275.
8. Duan X., Yonemitsu Y., Chou B., Yoshida K., Tanaka S., Hasegawa M., Tetsutani K., Ishida H., Himeno K., Hisaeda H. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2. Vaccine 2009, 27:6154-6159.
9. + memory stem cells. Nat. Med. 2009, 15:808-813.
10. Goulder P.J., Watkins D.I. HIV and SIV CTL escape: implications for vaccine design. Nat. Rev. Immunol. 2004, 4:630-640.
11. Hanke T., Goonetilleke N., McMichael A.J., Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J. Gen. Virol. 2007, 88:1-12.
12. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., Legasse A.W., Axthelm M.K., Oswald K., Trubey C.M., Piatak M., Lifson J.D., Nelson J.A., Jarvis M.A., Picker L.J. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 2009, 15:293-299.
13. Haolla F.A., Claser C., de Alencar B.C., Tzelepis F., de Vasconcelos J.R., de Oliveira G., Silverio J.C., Machado A.V., Lannes-Vieira J., Bruna-Romero O., Gazzinelli R.T., dos Santos R.R., Soares M.B., Rodrigues M.M. Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection. Vaccine 2009, 27:5644-5653.
14. Harari A., Dutoit V., Cellerai C., Bart P.A., Du Pasquier R.A., Pantaleo G. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol. Rev. 2006, 211:236-254.
15. Hoffmann E., Neumann G., Kawaoka Y., Hobom G., Webster R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. USA 2000, 97:6108-6113.
16. + T cell differentiation during viral infection. Immunity 2007, 27:393-405.
17. Katae M., Miyahira Y., Takeda K., Matsuda H., Yagita H., Okumura K., Takeuchi T., Kamiyama T., Ohwada A., Fukuchi Y., Aoki T. Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy. Infect. Immun. 2002, 70:4833-4840.
18. Kedzierska K., La Gruta N.L., Stambas J., Turner S.J., Doherty P.C. Tracking phenotypically and functionally distinct T cell subsets via T cell repertoire diversity. Mol. Immunol. 2008, 45:607-618.
19. Khanolkar A., Fuller M.J., Zajac A.J. CD4 T cell-dependent CD8 T cell maturation. J. Immunol. 2004, 172:2834-2844.
20. Laouar A., Manocha M., Haridas V., Manjunath N. Concurrent generation of effector and central memory CD8 T cells during vaccinia virus infection. PLoS ONE 2008, 3:e4089.
21. Létourneau S., Krieg C., Pantaleo G., Boyman O. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J. Allergy Clin. Immunol. 2009, 123:758-762.
22. Machado A.V., Cardoso J.E., Claser C., Rodrigues M.M., Gazzinelli R.T., Bruna-Romero O. Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. Hum. Gene Ther. 2006, 17:898-908.
23. Masopust D., Ha S.J., Vezys V., Ahmed R. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J. Immunol. 2006, 177:831-839.
24. Masopust D., Vezys V., Wherry E.J., Ahmed R. A brief history of CD8 T cells. Eur. J. Immunol. 2007, 37(Suppl. 1):S103-S110.
25. Masopust D. Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location. J. Intern. Med. 2009, 265:125-137.
26. int memory CD8 T cell subset generated under sterile inflammatory conditions. J. Immunol. 2009, 182:3846-3854.
27. McMurry J.A., Moise L., Gregory S.H., De Groot A.S. Tularemia vaccines - an overview. Med. Health R. I. 2007, 90:311-314.
28. Miyahira Y., Dvorak J.A. Kinetoplastidae display naturally occurring ancillary DNA-containing structures. Mol. Biochem. Parasitol. 1994, 65:339-349.
29. + T cells using an ELISPOT assay. J. Immunol. Methods 1995, 181:45-54.
30. + responses in mice. Proc. Natl. Acad. Sci. USA 1998, 95:3954-3959.
31. + T cell-mediated protective immunity against Trypanosoma cruzi. Int. Immunol. 1999, 11:133-141.
32. + T cell response by DNA and viral vector vaccination. J. Immunol. 2003, 171:6344-6348.
33. Miyahira Y., Katae M., Kobayashi S., Takeuchi T., Fukuchi Y., Abe R., Okumura K., Yagita H., Aoki T. Critical contribution of CD28-CD80/CD86 costimulatory pathway to protection from Trypanosoma cruzi infection. Infect. Immun. 2003, 71:3131-3137.
34. Miyahira Y., Katae M., Takeda K., Yagita H., Okumura K., Kobayashi S., Takeuchi T., Kamiyama T., Fukuchi Y., Aoki T. Activation of natural killer T cells by α-galactosylceramide impairs DNA vaccine-induced protective immunity against Trypanosoma cruzi. Infect. Immun. 2003, 71:1234-1241.
35. +-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect. Immun. 2005, 73:7356-7365.
36. + T cell immunity - an infection model for developing T cell vaccine. Parasitol. Int. 2008, 57:38-48.
37. Muller U., Sobek V., Balkow S., Holscher C., Mullbacher A., Museteanu C., Mossmann H., Simon M.M. Concerted action of perforin and granzymes is critical for the elimination of Trypanosoma cruzi from mouse tissues, but prevention of early host death is in addition dependent on the FasL/Fas pathway. Eur. J. Immunol. 2003, 33:70-78.
38. + T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus. Vaccine 2000, 18:1863-1869.
39. + T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response. Immunol. Rev. 2008, 225:272-283.
40. + T cell responses. J. Exp. Med. 2007, 204:1405-1416.
41. Quinlivan M., Zamarin D., Garcia-Sastre A., Cullinane A., Chambers T., Palese P. Attenuation of equine influenza viruses through truncations of the NS1 protein. J. Virol. 2005, 79:8431-8439.
42. Radosević K., Rodriguez A., Lemckert A., Goudsmit J. Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects. Expert Rev. Vacc. 2009, 8:577-592.
43. Reyes-Sandoval A., Harty J.T., Todryk S.M. Viral vector vaccines make memory T cells against malaria. Immunology 2007, 121:158-165.
44. + T-cell responses. Infect. Immun. 2010, 78:145-153.
45. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J. Exp. Med. 2008, 205:7-12.
46. Shiver J.W., Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 2004, 55:355-372.
47. Solorzano A., Webby R.J., Lager K.M., Janke B.H., Garcia-Sastre A., Richt J.A. Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J. Virol. 2005, 79:7535-7543.
48. Stambas J., Guillonneau C., Kedzierska K., Mintern J.D., Doherty P.C., La Gruta N.L. Killer T cells in influenza. Pharmacol. Ther. 2008, 120:186-196.
49. Stephenson J.R. Genetically modified viruses: vaccines by design. Curr. Pharm. Biotechnol. 2001, 2:47-76.
50. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 1992, 89:10847-10851.
51. Tarleton R.L., Koller B.H., Latour A., Postan M. Susceptibility of β2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature 1992, 356:338-340.
52. Tsuji M., Miyahira Y., Nussenzweig R.S., Aguet M., Reichel M., Zavala F. Development of antimalaria immunity in mice lacking IFN-γ receptor. J. Immunol. 1995, 154:5338-5344.
53. Vezys V., Yates A., Casey K.A., Lanier G., Ahmed R., Antia R., Masopust D. Memory CD8 T-cell compartment grows in size with immunological experience. Nature 2009, 457:196-199.
54. Vuola J.M., Keating S., Webster D.P., Berthoud T., Dunachie S., Gilbert S.C., Hill A.V. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. 2005, 174:449-455.
55. Wherry E.J., Teichgraber V., Becker T.C., Masopust D., Kaech S.M., Antia R., von Andrian U.H., Ahmed R. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 2003, 4:225-234.
56. + T cell responses. Immunity 2006, 25:533-543.
57. + T cells. Virology 2001, 280:155-159.
58. Zhao Y., De Trez C., Flynn R., Ware C.F., Croft M., Salek-Ardakani S. The adaptor molecule MyD88 directly promotes CD8 T cell responses to vaccinia virus. J. Immunol. 2009, 182:6278-6286.